Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.61 |
| ▸ | GAA | P10253 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.58 |
| ▸ | WDR5 | P61964 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036125 | 0.87 | ALDH1A1 (0.49) | ALDH1A1GAALMNAHPGDKMT2A | |
| SCHEMBL29399979 | 0.87 | ALDH1A1 (0.49) | ALDH1A1GAALMNAHPGDKMT2A | |
| SCHEMBL5181158 | 0.86 | GAA (0.67) | ALDH1A1GAALMNAHPGDKMT2A | |
| SCHEMBL30721918 | 0.84 | GAA (0.69) | ALDH1A1GAALMNAHPGDKMT2A | |
| SCHEMBL26984503 | 0.84 | GAA (0.69) | ALDH1A1GAALMNAHPGDKMT2A | |
| SCHEMBL30410222 | 0.83 | ALDH1A1 (0.61) | ALDH1A1GAALMNAKMT2AMEN1 | |
| SCHEMBL28532931 | 0.83 | ALDH1A1 (0.58) | ALDH1A1GAALMNAHPGDKMT2A | |
| SCHEMBL15961236 | 0.83 | SIRT6 (0.59) | ALDH1A1GAALMNAKMT2AMEN1 | |
| SCHEMBL3313887 | 0.83 | GAA (0.72) | ALDH1A1GAALMNAKMT2AMEN1 | |
| SCHEMBL2461666 | 0.83 | ALDH1A1 (0.66) | ALDH1A1GAALMNAHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| US-8815872-B2 | Macrocyclics pyrimidines as aurora kinase inhibitors | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815872-B2 | Macrocyclics pyrimidines as aurora kinase inhibitors | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20110294801-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294801-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| WO-2010028116-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | ALDH1A1 999/4885GAA 4133/4885LMNA 1830/4885 |
| US-20110294801-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | AURKC, AURKA, AURKB | ALDH1A1 4424/4885GAA 2546/4885LMNA 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.